[Study on intravascular pressure change during sclerotherapy for cavernous hemangiomas (CHs)].
To investigate the regulation and significance of the intravascular pressure change of cavernous hemangiomas during the treatment of sclerotherapy, we did observations in 29 cases with slowing down the efferent blood flow of the CHs in their treatment. It was found that the baseline intravascular pressure of CHs is 5-15 mmHg, the lowest being at the neck. The efferent rate of CHs is higher than the afferent rate. The higher the efferent rate, the more times of injection and more amount of thrombotic agent were needed. At the beginning of the thrombosis, the CHs pressure rose gradually to a flat curve, which suggested that the efferent veins were being thrombosed one by one. Then the CHs pressure curve became a blunt peak, which suggested that all the efferent veins were thrombosed and it was time to inject the sclerosing agent. Finally the CHs pressure curve became a sharp peak, suggesting that the whole CHs was thrombosed and sclerosed. Follow-up from 6 months to 3 years revealed that CHs disappeared in 26 of 29 cases, recurred in 3 cases. No severe complications were found. The authors concluded that the treatment can improve the curative effect and decrease complications.
Ouyang
T
T
Department of Plastic Surgery, Changhai Hospital, Second Military Medical University, Shanghai.
Guo
E
E
D000293:Adolescent; D000328:Adult; D001794:Blood Pressure; D002648:Child; D002675:Child, Preschool; D003974:Diatrizoate Meglumine / Q000627:therapeutic use*; D005260:Female; D006392:Hemangioma, Cavernous / Q000098:blood supply / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D012597:Sclerosing Solutions / Q000627:therapeutic use; D015911:Sclerotherapy
D012597:Sclerosing Solutions; D003974:Diatrizoate Meglumine